SGLT2 inhibitors have been shown in randomized trials to be effective in improving cardiovascular and renal outcomes. However, the populations in these studies were carefully selected, usually excluding patients under immunosuppression. The safety and efficacy of these drugs in people taking glucocorticoids was therefore previously unknown.
Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
